Idorsia
Viatris and Idorsia enter research and development collaboration
February 28, 2024Research and Development Idorsia, Pharmacy, Viatris, acute myocardial infarction, systemic lupus erythematosus
Viatris and Idorsia have announced that they have entered into agreements for a significant global research and development collaboration. Under …
Idorsia reveals it is working with Neurocrine on new epilepsy drug deal
January 10, 2020Medical Communications FDA, Idorsia, Neurocrine, drugs, epilepsy, pharma
Idorsia revealed its 2019 deal for its investigational epilepsy medicine was with Neurocrine Biosciences, and it is potentially worth more …
J&J opts in on Idorsia’s candidate for $230m
December 4, 2017Sales and Marketing Idorsia, Johnson & Johnson, biotech, drugs, pharma, pharmaceutical
As part of Johnson & Johnson’s acquisition of Actelion, it was able to secure a number of ties with the …
Actelion spin-off hit by blow shortly before buyout
June 9, 2017Medical Communications, Research and Development Actelion, Idorsia, J&J, JJ
Idorsia, the spin-off R&D company of Actelion, has been hit a blow even before it has left the ground. The …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
